$27.62
2.88% today
Nasdaq, Apr 03, 06:44 pm CET
ISIN
US00847X1046
Symbol
AGIO
Sector
Industry

Agios Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Agios Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
67%
Hold
33%

Agios Pharmaceuticals, Inc. Price Target

Target Price $54.57
Price $28.44
Potential
Number of Estimates 7
7 Analysts have issued a price target Agios Pharmaceuticals, Inc. 2026 . The average Agios Pharmaceuticals, Inc. target price is $54.57. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 6 Analysts recommend Agios Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Agios Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Agios Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 36.50 51.16
36.09% 40.15%
EBITDA Margin -1,150.90% -957.99%
19.80% 16.76%
Net Margin 1,822.86% -839.58%
235.12% 146.06%

9 Analysts have issued a sales forecast Agios Pharmaceuticals, Inc. 2025 . The average Agios Pharmaceuticals, Inc. sales estimate is

$51.2m
Unlock
. This is
40.15% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$78.3m 114.54%
Unlock
, the lowest is
$41.8m 14.63%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $36.5m 36.09%
2025
$51.2m 40.15%
Unlock
2026
$164m 219.95%
Unlock
2027
$378m 131.04%
Unlock
2028
$683m 80.58%
Unlock
2029
$1.0b 53.33%
Unlock

3 Analysts have issued an Agios Pharmaceuticals, Inc. EBITDA forecast 2025. The average Agios Pharmaceuticals, Inc. EBITDA estimate is

$-490m
Unlock
. This is
16.66% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-464m 10.51%
Unlock
, the lowest is
$-507m 20.69%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-420m 9.15%
2025
$-490m 16.66%
Unlock
2026
$-407m 16.91%
Unlock
2027
$-220m 45.97%
Unlock

EBITDA Margin

2024 -1,150.90% 19.80%
2025
-957.99% 16.76%
Unlock
2026
-248.78% 74.03%
Unlock
2027
-58.18% 76.61%
Unlock

5 Agios Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Agios Pharmaceuticals, Inc. net profit estimate is

$-430m
Unlock
. This is
165.91% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-366m 156.14%
Unlock
, the lowest is
$-506m 177.63%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $665m 283.89%
2025
$-430m 164.55%
Unlock
2026
$-357m 16.95%
Unlock
2027
$-238m 33.40%
Unlock
2028
$-83.7m 64.75%
Unlock
2029
$244m 390.78%
Unlock

Net Margin

2024 1,822.86% 235.12%
2025
-839.58% 146.06%
Unlock
2026
-217.92% 74.04%
Unlock
2027
-62.82% 71.17%
Unlock
2028
-12.26% 80.48%
Unlock
2029
23.26% 289.72%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 11.64 -7.51
283.89% 164.52%
P/E negative
EV/Sales 15.50

5 Analysts have issued a Agios Pharmaceuticals, Inc. forecast for earnings per share. The average Agios Pharmaceuticals, Inc. EPS is

$-7.51
Unlock
. This is
165.88% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-6.40 156.14%
Unlock
, the lowest is
$-8.85 177.63%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $11.64 283.89%
2025
$-7.51 164.52%
Unlock
2026
$-6.24 16.91%
Unlock
2027
$-4.16 33.33%
Unlock
2028
$-1.47 64.66%
Unlock
2029
$4.26 389.80%
Unlock

P/E ratio

Current 2.50 154.11%
2025
-3.78 251.20%
Unlock
2026
-4.56 20.63%
Unlock
2027
-6.84 50.00%
Unlock
2028
-19.41 183.77%
Unlock
2029
6.68 134.42%
Unlock

Based on analysts' sales estimates for 2025, the Agios Pharmaceuticals, Inc. stock is valued at an EV/Sales of

15.50
Unlock
and an P/S ratio of
31.85
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 21.72 37.91%
2025
15.50 28.65%
Unlock
2026
4.84 68.75%
Unlock
2027
2.10 56.72%
Unlock
2028
1.16 44.62%
Unlock
2029
0.76 34.78%
Unlock

P/S ratio

Current 44.64 27.13%
2025
31.85 28.65%
Unlock
2026
9.96 68.75%
Unlock
2027
4.31 56.72%
Unlock
2028
2.39 44.62%
Unlock
2029
1.56 34.78%
Unlock

Current Agios Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Feb 24 2025
Cantor Fitzgerald
Locked
Locked
Locked Dec 18 2024
RBC Capital
Locked
Locked
Locked Dec 10 2024
Scotiabank
Locked
Locked
Locked Dec 09 2024
RBC Capital
Locked
Locked
Locked Nov 01 2024
Scotiabank
Locked
Locked
Locked Nov 01 2024
Scotiabank
Locked
Locked
Locked Oct 16 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 24 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Dec 18 2024
Locked
RBC Capital:
Locked
Locked
Dec 10 2024
Locked
Scotiabank:
Locked
Locked
Dec 09 2024
Locked
RBC Capital:
Locked
Locked
Nov 01 2024
Locked
Scotiabank:
Locked
Locked
Nov 01 2024
Locked
Scotiabank:
Locked
Locked
Oct 16 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today